Journal Logo

Department: DRUG CHALLENGE

Infectious disease drugs

Dalal, Kavitha S. PharmD; Bridgeman, Mary Barna PharmD, BCPS, BCGP

Author Information
doi: 10.1097/01.NURSE.0000615148.13532.06
  • Free

CAN YOU IDENTIFY these infectious disease medications? To find out, match each brand name in Section I with its generic name in Section II.

Section I

______ 1. Xofluza (Shionogi)

______ 2. Nuzyra (Paratek Pharmaceuticals)

______ 3. Xerava (Tetraphase Pharmaceuticals)

Section II

a. omadacycline. This tetracycline-derived antibiotic is indicated to treat adults with community-acquired pneumonia and acute bacterial skin and skin structure infections. Considered a modernized tetracycline designed to combat tetracycline resistance, it has activity against Gram-positive, Gram-negative, and atypical organisms. Like other tetracycline-class drugs, this medication may cause permanent tooth discoloration and reversible inhibition of bone growth in infants and children when administered during the second and third trimesters of pregnancy.

b. baloxavir marboxil. This polymerase acidic endonuclease inhibitor is used to treat acute uncomplicated influenza in patients age 12 years and older who have been symptomatic for no more than 48 hours. It is given orally in a dose based on weight. Avoid coadministration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements containing calcium, iron, magnesium, selenium, or zinc. Monitor patients for secondary bacterial infections, which may coexist with an influenza infection.

c. eravacycline. Also a tetracycline-derived antibiotic, eravacycline is indicated to treat complicated intra-abdominal infections in patients age 18 and older. Administer it by I.V. infusion through a dedicated line or a Y-site over approximately 60 minutes every 12 hours for 4 to 14 days as prescribed. Flush the I.V. line with 0.9% sodium chloride before and after administration.

Answers: 1b, 2a, 3c

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.